

Overview of Inherited Heart Rhythm Disorders for Patients

Introduction

Inherited heart rhythm disorders affect a small portion of the population, presenting as palpitations, fainting, heart arrest and sudden death. Many patients present as teenagers or young adults, but can present as babies, young children or when elderly. Tragically, children and adolescents are often highly publicized victims of fatal inherited heart rhythm disorders. These can be broadly divided into conditions with a primary electrical basis [Long and Short QT syndromes (LQTS, SQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), Wolff-Parkinson White (WPW)], and disease of heart muscle that often present with arrhythmias including sudden death [hypertrophic cardiomyopathy (HCM), and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)]. If undetected, these disorders can lead to sudden cardiac death (SCD).

How common are these conditions?

Inherited heart rhythm disorders are considered rare conditions that are typically unfamiliar to much of the general population. Systematic evidence suggests that their prevalence is considerably higher than this perspective would support.

Table 1 Prevalence of inherited heart rhythm disorders.

Condition	Prevalence
Hypertrophic cardiomyopathy	1 in 500 ¹
Long QT syndrome	1 in 2,500 ²
Wolff Parkinson White	1 in 3,000 ³⁻⁵
Arrhythmogenic right ventricular cardiomyopathy*	1 in 1,000 to 1 in 5,000 ⁶
Brugada syndrome	1 in 5,000 ⁷
Catecholaminergic polymorphic ventricular tachycardia	1 in 10,000 ^{8,9}

* Arrhythmogenic right ventricular cardiomyopathy and arrhythmogenic right ventricular dysplasia are the same condition, and will be referred to as arrhythmogenic right ventricular cardiomyopathy (ARVC) in this document.

Clinical Presentation

The clinical presentation varies between patients and conditions, ranging from no symptoms to severe and frequently occurring symptoms¹⁰. Though palpitations may occur infrequently, the typical symptoms are syncope (fainting) and cardiac arrest. Most inherited heart rhythm disorders are caused by autosomal dominant mutations¹¹⁻¹³. This means that a single genetic defect is present that results in the clinical condition that is inherited or transmitted to 50% of offspring. Typically, an index case (termed proband) presents with fainting, cardiac arrest or sudden death, and family screening identifies other members that are affected but with little or no symptoms. Being genetically affected, however, does not necessarily mean that individuals will be symptomatic. Penetrance is the term used to describe the proportion of individuals who

possess the genetic mutation and are also symptomatic. The penetrance of inherited heart rhythm disorders is variable, ranging from 20-60%^{6, 14-17}. It is also important to note that patients who are symptomatic may experience symptoms to different degrees^{6, 10, 15, 18, 19}.

Fainting

Fainting (termed syncope) is a relatively common problem, with up to one in five individuals experiencing an episode by the time they reach 15 years of age²⁰, and a 30-50% lifetime prevalence^{21, 22}. Though it is often benign, fainting can be a sentinel sign of a more serious, underlying heart condition such as an inherited heart rhythm condition. Warning signs that are key involve unusual circumstances of fainting, such as during exercise, swimming, with loud noises or strong emotion.

While fainting is the most common symptom associated with inherited heart rhythm disorders, others symptoms may exist. These include, but are not limited to palpitations, dizziness, chest pain, and shortness of breath^{11, 23-27}.

Tragedies

A small proportion of patients who die suddenly remain unexplained after autopsy, that have presumed primary electrical disease attributed to inherited heart rhythm disorders²⁸. This type of sudden presumed electrical death is termed sudden arrhythmic death syndrome – SADS. Sudden death is a tragic but all too common manifestation of inherited heart rhythm disorders. Limited evidence suggests that fainting or other sentinel signs may precede sudden death on some occasions. Inherited heart rhythm disorders such as Long QT or Brugada Syndrome have no structural counterpart that is detectable at autopsy. Because the electrical system ceases to function at death, it is not possible to detect these conditions at autopsy. Family screening after a SADS death yielded a diagnosis in half of families, identifying family members with the whole range of inherited heart rhythm disorders, most commonly Long QT Syndrome²⁹.

Recent advances in the genetic testing for these conditions has enabled researchers to perform genetic testing on the DNA from the sudden death victim, termed “molecular autopsy”. This process has been applied to a small number of sudden death victims, and suggests that an explanation can be detected in almost half of the victims. This provides an explanation for the sudden death that would otherwise be unexplained, and permits screening of the remaining family members to prevent further tragedy³⁰⁻³⁴.

Changing the perspective to patients with a diagnosed inherited heart rhythm disorders, the risk of sudden death is highly variable. In general, the lifetime risk of sudden death in Long QT Syndrome is 4%^{25, 35-42}, but this estimate is derived from a high-risk population that is untreated. The majority of these patients had fainting before they died. Other inherited heart rhythm disorders have been less well studied, and the resultant risk of sudden death is less well established.^{11, 17, 43-45}

Risk factors for sudden death can be identified for many of these conditions, typically a combination of symptoms (most often syncope) and ECG and monitoring measures. It is crucial for inherited heart rhythm disorders to be detected as soon as possible, as death may be the first clinical presentation of the disease.

Diagnosis

Many tests are currently used for identifying and diagnosing inherited heart rhythm disorders. The key “test” is a careful account of patient symptoms and a family history. Inherited heart rhythm disorders often present with symptoms in unusual circumstances such as swimming, loud noises or during exercise. Details of fainting and sudden death are key to direct testing. After this, testing includes assessment of the structure of the heart with imaging (ultrasound of the heart (called an echocardiogram) and MRI), and the function of the electrical system with an ECG, heart monitoring, exercise testing, electrophysiologic testing and drug provocation^{50, 57}.

Genetic testing is often used for detecting the genetic basis of the condition in a patient who is affected by an inherited heart rhythm disorder, or for screening family members to help confirm a diagnosis²⁰. The yield of genetic testing is variable in the different inherited heart rhythm disorders, and is strongly influenced by the likelihood of the diagnosis based on clinical testing. Patients that undergo genetic testing should be educated in the reasons for testing, the complexity of interpretation and the implications for them.

Treatment

Depending on whether the patient is symptomatic or asymptomatic, several treatment approaches may be considered. These include lifestyle recommendations to reduce risk, medications and occasional use of an implantable cardioverter-defibrillator (ICD)⁴⁶⁻⁵⁰. More details regarding treatment of specific conditions is available under each section, and should be discussed with your doctor.

Discussion

Inherited heart rhythm disorders affect more individuals than previously appreciated. As scientific research continues to push forward, the tools and techniques for diagnosing and treating will continue to improve. In order to effectively treat these heart conditions, early recognition is crucial. Recognizing symptoms can be difficult, as individuals may not experience any, or may fail to seek medical attention because they feel their symptoms are unrelated to a heart condition. Increasing public education of the signs and symptoms of inherited heart arrhythmias will facilitate early detection and preventive therapy.

Once an individual is diagnosed with an inherited heart rhythm disorder, steps can be taken towards an effective treatment plan. With most conditions, treatment preceding the development of symptoms is virtually completely protective. As an example,

treatment in asymptomatic patients with Long QT Syndrome can help prevent a life-threatening arrhythmic event.

For those with inherited heart rhythm disorders, the future looks promising. Genetic analysis allows for family members of affected individuals to be tested. If positive, treatment can be initiated before the onset of symptoms. Early diagnosis of inherited heart rhythm disorders and initiation of treatment may prevent fatal arrhythmic events. The continued funding and support of medical research, as well as the enhancement of public awareness of inherited arrhythmias ensures that the lives of those affected will continue to improve.

Selected References

1. Shephard R, Semsarian C. Advances in the prevention of sudden heart death in the young. *Ther Adv Cardiovasc Dis* 2009;3:145-55.
2. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. *Curr Probl Cardiol* 2008;33:629-94.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of electrocardiographic preexcitation in men. The Manitoba Follow-up Study. *Ann Intern Med* 1992;116:456-60.
4. Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assessment of asymptomatic patients with the Wolff-Parkinson-White electrocardiographic pattern. *N Engl J Med* 1989;320:1229-33.
5. Berkman NL, Lamb LE. The Wolff-Parkinson-White electrocardiogram. A follow-up study of five to twenty-eight years. *N Engl J Med* 1968;278:492-4.
6. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. *Lancet* 2009;373:1289-300.
7. Gallagher MM, Forleo GB, Behr ER, et al. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. *Int J Cardiol* 2008;130:44-8.
8. Liu N, Colombi B, Raycheva-Buono EV, Bloise R, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. *Herz* 2007;32:212-7.
9. Priori SG, Napolitano C. Genetics of heart arrhythmias and sudden heart death. *Ann N Y Acad Sci* 2004;1015:96-110.
10. Gimeno JR, Lacunza J, Garcia-Alberola A, et al. Penetrance and risk profile in inherited heart diseases studied in a dedicated screening clinic. *Am J Cardiol* 2009;104:406-10.
11. Kaufenstein S, Kiehne N, Neumann T, Pitschner HF, Bratzke H. Heart gene defects can cause sudden heart death in young people. *Dtsch Arztebl Int* 2009;106:41-7.
12. Roberts R, Gollob M. Molecular cardiology and genetics in the 21st century--a primer. *Curr Probl Cardiol* 2006;31:637-701.
13. Roberts R. Genomics and heart arrhythmias. *J Am Coll Cardiol* 2006;47:9-21.
14. Moric E, Herbert E, Trusz-Gluzza M, Filipecki A, Mazurek U, Wilczok T. The implications of genetic mutations in the sodium channel gene (SCN5A). *Europace* 2003;5:325-34.
15. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. *Circulation* 1999 Feb 2;99:529-33.
16. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ. Spectrum and frequency of heart channel defects in swimming-triggered arrhythmia syndromes. *Circulation* 2004;110:2119-24.
17. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. *Circulation* 2002 Jul 2;106:69-74.
18. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *J Am Coll Cardiol* 2007;50:1813-21.
19. Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Nat Clin Pract Cardiovasc Med* 2008;5:258-67.
20. McLeod KA. Syncope in childhood. *Arch Dis Child* 2003;88:350-3.
21. Serletis A, Rose S, Sheldon AG, Sheldon RS. Vasovagal syncope in medical students and their first-degree relatives. *Eur Heart J* 2006;27:1965-70.
22. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. *N Engl J Med* 2002 Sep 19;347:878-85.
23. Johnson JN, Hofman N, Haglund CM, Cascino GD, Wilde AA, Ackerman MJ. Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy. *Neurology* 2009;72:224-31.
24. Goldenberg I, Moss AJ, Zareba W. Sudden heart death without structural heart disease: update on the long QT and Brugada syndromes. *Curr Cardiol Rep* 2005;7:349-56.
25. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation* 2001;103:89-95.
26. Garson A, Jr., Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients [see comments]. *Circulation* 1993;87:1866-72.
27. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome [see comments]. *N Engl J Med* 1992;327:846-52.
28. Wren C, O'Sullivan JJ, Wright C. Sudden death in children and adolescents. *Heart* 2000;83:410-3.
29. Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. *Lancet* 2003;362:1457-9.

30. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. *J Am Coll Cardiol* 2007;49:240-6.
31. Tester DJ, Ackerman MJ. The role of molecular autopsy in unexplained sudden heart death. *Curr Opin Cardiol* 2006;21:166-72.
32. Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. *JAMA* 2001 Nov 14;286:2264-9.
33. Ackerman MJ, Tester DJ, Driscoll DJ. Molecular autopsy of sudden unexplained death in the young. *Am J Forensic Med Pathol* 2001;22:105-11.
34. Rutberg J, Green MS, Gow RM, et al. Molecular autopsy in the sudden heart death of a young woman: a first Canadian report. *Can J Cardiol* 2007;23:904-6.
35. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and heart events among patients treated with beta-blockers. *Jama* 2004;292:1341-4.
36. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. *N Engl J Med* 2003;348:1866-74.
37. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. *Circulation* 2002;105:794-9.
38. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. *Circulation* 1999 Dec 14;100:2431-6.
39. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. *Circulation* 1991;84:1136-44.
40. Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted heart arrest and sudden heart death in children with the congenital long-QT syndrome. *Circulation* 2008;117:2184-91.
41. Goldenberg I, Moss AJ, Bradley J, et al. Long-QT syndrome after age 40. *Circulation* 2008;117:2192-201.
42. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. *J Am Coll Cardiol* 2007;49:329-37.
43. Marks AR, Priori S, Memmi M, Kontula K, Laitinen PJ. Involvement of the heart ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. *J Cell Physiol* 2002 Jan;190:1-6.
44. Corrado D, Leoni L, Link MS, et al. Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. *Circulation* 2003.
45. Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ. Long-term follow-up in patients with arrhythmogenic right ventricular disease. *Eur Heart J* 1989;10 Suppl D:68-73.
46. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden heart death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. *Circulation* 2008;118:1497-518.
47. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden heart death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Heart Death). *J Am Coll Cardiol* 2006;48:e247-346.
48. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). *Eur Heart J* 2006;27:1979-2030.
49. Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. *Circulation* 2006;113:316-27.
50. Tang AS, Ross H, Simpson CS, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. *Can J Cardiol* 2005;21 Suppl A:11-8.